Asthma drug by GSK given green light for use in China
Pharmaceutical company GSK announced on Wednesday that its novel targeted biological agent Nucala has been approved in China to treat a type of severe asthma.
Nucala will be used for maintenance treatment of severe eosinophilic asthma (SEA) in adults and adolescents aged 12 and above.
SEA accounts for the largest number of severe asthma cases.
The drug is expected to provide an advanced disease management approach for millions of Chinese patients suffering from this respiratory disease, said the company.
GSK said the approval was given following an independent, Phase III clinical trial involving Chinese patients that yielded positive results.
There are roughly 46 million adults in China who suffer from asthma, with about 6 percent suffering from severe asthma.
- National Games showcase Guangdong, Hong Kong, Macao cuisine
- Xiangyang legislators expand public feedback channels
- Beijing court cracks down on medical fraud cases
- Gambling ringleader sent back to China
- Intl experts raise alarm over the accelerating loss of biodiversity
- China's power battery industry records nearly 50% jump in sales
